Edwards Lifesciences Corporation
Edwards Lifesciences Corporation (EW) Financial Performance & Income Statement Overview
Review Edwards Lifesciences Corporation (EW) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Edwards Lifesciences Corporation (EW) Income Statement & Financial Overview
Review Edwards Lifesciences Corporation EW income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $1.41B | $1.39B | $1.35B | $1.39B |
| Cost of Revenue | $300.20M | $292.20M | $262.90M | $297.80M |
| Gross Profit | $1.11B | $1.09B | $1.09B | $1.09B |
| Gross Profit Ratio | $0.79 | $0.79 | $0.81 | $0.79 |
| R&D Expenses | $254.60M | $271.10M | $253.40M | $272.60M |
| SG&A Expenses | $465.70M | $491.90M | $421.40M | $450.80M |
| Operating Expenses | $702.60M | $781.00M | $698.50M | $723.40M |
| Total Costs & Expenses | -$1.003B | $1.07B | $960.10M | $1.02B |
| Interest Income | $36.50M | $44.20M | $24.30M | $15.50M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $42.60M | $34.50M | $39.60M |
| EBITDA | $433.90M | $483.70M | $437.30M | $416.80M |
| EBITDA Ratio | $0.31 | $0.35 | $0.32 | $0.30 |
| Operating Income | $409.90M | $312.60M | $394.30M | $364.70M |
| Operating Income Ratio | $0.29 | $0.23 | $0.29 | $0.26 |
| Other Income/Expenses (Net) | $24.00M | $77.50M | $8.50M | $17.50M |
| Income Before Tax | $433.90M | $390.10M | $402.80M | $386.60M |
| Income Before Tax Ratio | $0.31 | $0.28 | $0.30 | $0.28 |
| Income Tax Expense | $70.30M | $45.10M | $40.70M | $20.20M |
| Net Income | $358.00M | $385.60M | $3.07B | $366.30M |
| Net Income Ratio | $0.25 | $0.28 | $2.27 | $0.26 |
| EPS | $0.61 | $0.65 | $5.14 | $0.61 |
| Diluted EPS | $0.61 | $0.65 | $5.13 | $0.61 |
| Weighted Avg Shares Outstanding | $586.90M | $589.80M | $597.20M | $602.10M |
| Weighted Avg Shares Outstanding (Diluted) | $587.80M | $590.50M | $598.10M | $604.30M |
Over the last four quarters, Edwards Lifesciences Corporation achieved steady financial progress, growing revenue from $1.39B in Q2 2024 to $1.41B in Q1 2025. Gross profit stayed firm with margins at 79% in Q1 2025 versus 79% in Q2 2024. Operating income totaled $409.90M in Q1 2025, maintaining a 29% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $433.90M. Net income dropped to $358.00M, with EPS at $0.61. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan